Atezolizumab + Bevacizumab +/- Tiragolumab for Liver Cancer
(SKYSCRAPER-14 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a combination of three drugs—tiragolumab, atezolizumab, and bevacizumab—to treat advanced liver cancer that cannot be removed by surgery. These drugs help the immune system fight cancer and cut off the tumor's blood supply. The goal is to see if this combination is safe and effective for these patients.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop your current medications. However, you cannot have had prior systemic treatment for liver cancer or be on systemic immunosuppressive or immunostimulatory medications.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it excludes those on systemic immunosuppressive or immunostimulatory medications, so you might need to stop those if you're taking them.
What safety data is available for the treatment of atezolizumab plus bevacizumab for liver cancer?
The combination of atezolizumab and bevacizumab has been approved by the FDA for the treatment of advanced hepatocellular carcinoma (HCC) based on the IMbrave150 study. Common adverse reactions in more than 20% of patients include hypertension, fatigue/asthenia, and proteinuria. Hemorrhage was reported in 25% of patients. The treatment has shown improved overall survival and progression-free survival compared to sorafenib, a standard treatment. Safety evaluations, including checking for varices, are recommended before starting treatment. Additional studies have confirmed the safety and efficacy of this combination in various patient populations, including older adults and those with viral infections.12345
Is the combination of Atezolizumab and Bevacizumab safe for liver cancer patients?
The combination of Atezolizumab and Bevacizumab has been approved for liver cancer and is generally considered safe, but common side effects include high blood pressure, tiredness, and protein in the urine. There is also a higher risk of bleeding, so patients should be checked for certain conditions before starting treatment.12346
Is the drug Atezolizumab, Bevacizumab, Tiragolumab promising for liver cancer?
What makes the drug combination of Atezolizumab, Bevacizumab, and Tiragolumab unique for liver cancer?
The combination of Atezolizumab and Bevacizumab is already a standard first-line treatment for advanced liver cancer, known for improving survival compared to older treatments. Adding Tiragolumab, which is an immune checkpoint inhibitor, could potentially enhance the immune response against cancer cells, making this combination a novel approach in liver cancer treatment.278910
What data supports the idea that Atezolizumab + Bevacizumab +/- Tiragolumab for Liver Cancer is an effective drug?
The available research shows that the combination of atezolizumab and bevacizumab is more effective than sorafenib, an older treatment, for liver cancer that cannot be removed by surgery. This combination has become the standard first choice for treating advanced liver cancer. Studies have shown that it helps patients live longer and is considered safe for older patients as well. It was approved in 2020 as a first-line treatment, meaning it's the first option doctors consider for advanced liver cancer.268911
What data supports the effectiveness of the drug combination Atezolizumab and Bevacizumab for liver cancer?
The combination of Atezolizumab and Bevacizumab has been shown to be more effective than Sorafenib for treating advanced liver cancer, leading to its approval as a first-line treatment. This combination increases overall survival and has become the standard of care for patients with unresectable liver cancer.268911
Who Is on the Research Team?
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Are You a Good Fit for This Trial?
This trial is for adults with advanced liver cancer (HCC) who haven't had systemic treatment before. They should be in good enough health to participate, not have a history of certain lung or autoimmune diseases, and can't be pregnant or breastfeeding. Men and women must use contraception to prevent pregnancy during the trial.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive atezolizumab and bevacizumab, with or without tiragolumab, every 3 weeks until unacceptable toxicity or loss of clinical benefit
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Atezolizumab
- Bevacizumab
- Tiragolumab
Atezolizumab is already approved in United States, European Union for the following indications:
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hoffmann-La Roche
Lead Sponsor
Dr. Levi Garraway
Hoffmann-La Roche
Chief Medical Officer since 2019
MD from the University of Basel
Dr. Thomas Schinecker
Hoffmann-La Roche
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University
Chugai Pharmaceutical
Industry Sponsor
Dr. Osamu Okuda
Chugai Pharmaceutical
Chief Executive Officer since 2020
MD from Kyoto University
Dr. Mariko Y. Momoi
Chugai Pharmaceutical
Chief Medical Officer
MD from Jichi Medical University